A few in vivo models of K-RAS mutant pancreatic cancers have been described to be sensitive to MEK inhibition, whereas K-RAS mutations have been shown to be predictive of resistance to treatment with PI3K inhibitors in several tumor types [17]–[19]. This evidence concerns the gene MAP2K7 and neoplasm.